Welcome to Innovation Focus

November 2020

Conference Highlights

The 68th ASMS Conference – ‘Rebooted’

Thousands of scientists attended the rebooted edition of the 68th ASMS conference this year to present and discover the latest research in and around the field of mass spectrometry. Given the current COVID-19 pandemic, scientific researchers were still able to attend ASMS 2020, in an accessible ‘reboot’ form. Viewed all over the world from offices and homes, the on demand presentations, live recordings, short courses and poster presentations were a big success. Highlights from SCIEX during the virtual conference are highlighted below.

SCIEX presented the Echo® MS System at the ASMS Reboot.

The Echo® MS System is an ultra-high sample throughput system that delivers speed, scale and reproducibility with unyielding data quality. The system leverages industry-leading quantitative MS technology from SCIEX to provide a highly sensitive solution featuring:

  • Speed: Analyze up to 3 samples per second to deliver quantitative results up to 50 times faster than conventional LC-MS.
  • Scale: Project timelines are transformed from weeks into days, while retaining precise, information-rich answers that enable critical decisions to be made faster.
  • Reproducibility: Experience unparalleled standards of quantification with consistent and precise reproducibility even in challenging matrices.

SCIEX presents Echo® MS System at ASMS Reboot – Press Release

If you missed any of our live events from the ASMS 2020 virtual scientific series they are available now on-demand. Experience a brand new technology announcement redefining high-throughput mass spectrometry, the role mass spec is playing in COVID-19 research and new analytical techniques for emerging applications.

ASMS 2020 on-demand content is waiting for you!

Access each of the recorded seminars below.

SCIEX presents RUN FAST – Get ready to redefine your definition of high-throughput, quantitative mass spectrometry
The SCIEX Innovation Team
Watch now >

The SCIEX flexible solution for MAM
Zoe Zhang, Application Support Senior Scientist, SCIEX
Watch now >

COVID-19: Highlighting the rapid response of researchers across the globe and the role mass spectrometry is playing
Prof. Markus Ralser, Ph.D., Charité – Universitätsmedizin and Francis Crick Institute
Watch now >

Benjamin Schwarz, Ph.D., Rocky Mountain National Lab, NIH/NIAID
Watch now >

Comprehensive LC-MS solutions for therapeutic oligonucleotides from characterization to quantification
Esme Candish, Biopharma Application Scientist, SCIEX
Watch now >

Customers Talk, We Listen​

Go Beyond with the SCIEX Triple Quad™ 7500 LC-MS/MS System – QTRAP® Ready

June 9 marked a special day for SCIEX. After much anticipation, the SCIEX Triple Quad™ 7500 System ꟷ QTRAP® Ready made its debut. This system delivers the highest level of sensitivity in the SCIEX portfolio and enables customers to Go Beyond previous limits of quantification.

The SCIEX 7500 System wouldn’t have been possible without the strong collaboration and feedback of our customers. In the definition phase, more than 40 customers were asked to provide feedback on what would help them be more efficient and successful with their use of mass spectrometry in their lab. During the hardware development phase, more than 10 customer collaborators were invited to evaluate early breadboard and prototype systems with their assays. The work from some of these collaborations resulted in the technical notes that can be found on the SCIEX 7500 website. Many thanks to our customers who participated in these activities!

Read more

Key highlights of the SCIEX 7500 System

The D Jet™ Ion guide efficiently captures and transits the ions into the high gas flow behind the orifice plate. The tapered dodecapole geometry of the D Jet Ion guide focuses the ions into the second stage QJet® Ion Guide. The D Jet ion guide, in partnership with the OptiFlow Pro Ion source with E Lens™ technology, results in an average of 7x improvement in sensitivity.

The OptiFlow® Pro Ion source is the next generation of the OptiFlow technology that was introduced in 2018. Our customers helped to shape the design of the source by providin crucial feedback that allowed SCIEX to deliver the technology needed to make operating a system easier. The OptiFlow Pro ion source, designed with extensibility in mind, is only available on the SCIEX 7500 system with Analytical flow ESI, microflow ESI and APCI modes of ionization.

The SCIEX 7500 System marks the first time that SCIEX is launching a triple quadrupole system powered by SCIEX OS software.

SCIEX OS delivers real usability, efficiency and integrity for your entire lab. Built on unique algorithms, SCIEX OS automates key steps of analysis, streamlines all your workflows, and enables you to make informed decisions quickly. The development of SCIEX OS software has always been in partnership with our collaborators who provide valuable feedback. POWERING UP INNOVATION, only when hardware and software are designed together can true innovation be realized. SCIEX OS connects the scientist with cutting edge technology and tools that enable them to combine their data with the global desire for answers. SCIEX OS Software will be the foundation for all new SCIEX innovations today and in the future.

Feature Article

Connecting with SCIEX Innovation Advisory Board members during the COVID-19 pandemic

The COVID-19 pandemic has challenged the foundations of business and life across the globe. The viral spread has necessitated rapid change at both the individual and organizational level. In June, we conducted a series of interviews with our Innovation Advisory Board (IAB) members to get insight into how their laboratories have adapted to COVID-19. We found that through adversity, we become resilient.

The personal and professional stories we heard placed the global experience on a very human level. In one interview, an IAB member cited an article in “The Guardian” that was the catalyst for both their personal and professional pandemic journey. One particular quote from that article stood out to us:

“If we turn our gaze to the more distant future, the future which is unknown both to you and to us too, we can only tell you this: when all of this is over, the world won’t be the same.”

When it comes to the changing life sciences world, we learned that organizations and research institutions alike are experiencing challenges. Some experienced the cascade effect of product or research delays or paused research caused by shutting down to prevent viral spread, while others experienced extreme ramp-ups to run clinical laboratories 24/7 to keep up with high sample processing volumes. We also heard about struggles with the delivery and receipt of supplies, such as reagents, due to supply chain disruptions, and the proactive accumulation of inventory in anticipation of an extended lockdown in the future.

The use of lab space, which is critical to general operations in a normal world, is another affected area. The need to incorporate new standard operating procedures to practice social distancing puts a new spin on things, as does building in daily routines for sanitization protocols between working shifts and complying with new government regulations. Many cited a need for solutions to efficiently manage workflow processes, both virtually and on-site, as well as new systems to assign laboratory space to help meet social distancing requirements.

On the whole, we learned that life science professionals continue to find new ways of working remotely, whether they are conducting virtual lectures in an academic setting or practical research on projects outside the lab. Many have been taking this time to write up the valuable research they have been doing for publication. Others have pivoted to new areas of research directly related to COVID-19, such as vaccines and immunology, and some have joined forces with other institutions to collectively battle COVID-19. Overall, there is a heightened sense of urgency and the need for fast, reliable, quality results.

We want to thank our IAB members for their time and candid feedback. Thinking again of the previously mentioned quote, though the world won’t be the same, the scientific community is taking action to resolve these problems and bring about fundamental change.

Accelerating your response to COVID-19

As the race continues to discover new drugs and vaccines that will help with the fight against COVID-19, drug repurposing is making headlines.

Remdesivir, chloroquine and the combination of lopinavir/ritonavir are just a few recent examples of existing drugs that are being analyzed to determine if they are candidates for treating novel diseases.
Unfortunately, the process of rediscovering drugs to identify novel treatment opportunities can be costly and difficult. Speed is of the essence and having the right information at every stage is vital to bringing safe and effective therapies to market faster.
Learn more about repurposing drug molecules at our COVID-19 resource portal. SCIEX can help you accelerate project timelines to get the precise, accurate results necessary to make critical decisions during this unprecedented time.

Using ultra-high-throughput proteomics to discover new biomarkers to predict COVID-19 severity

What if we could determine how severely COVID-19 will affect different individuals?

Theoretically, the ability to identify which patients are more likely to have a severe illness could allow medical professionals to take action earlier and administer treatments that would improve patient outcomes.

Dr. Markus Ralser—Einstein Professor of Biochemistry and Head of Biochemistry at Charité – Universitätsmedizin Berlin and Group Leader of Molecular Biology, Metabolism Laboratory at The Francis Crick Institute—is one researcher working to determine just that. He and the other authors of a recent study published in Cell Systems examined the use of a new ultra-high-throughput proteomics method to identify 27 blood biomarkers that distinguished COVID-19 patients with mild or severe responses.

Learn more from this interview with Dr. Ralser in Technology Networks, where he discusses the study and its possible implications.

The StatusScope® Remote Monitoring Service: Welcome to your connected lab

During the current pandemic, remote working solutions have become a must. That’s why our team is working hard to refine our products and services to meet your ever-changing needs.

We recently announced the release of the next-generation SCIEX StatusScope® Remote Monitoring Service. Built on an industry-leading cloud platform with enhanced security, StatusScope Remote Monitoring provides you with both the ultimate user experience and the peace of mind that comes with knowing your data is secure.

Want to learn more? Watch this video on Introducing SCIEX StatusScope® Remote Monitoring Service 2.0.

Survey Results​

Tips and Tricks​

SCIEX OS Software – Automatic Method Building

Creates one method for samples with different MRM transitions:
This video explores the automatic method building function that can create one method for samples with different MRM transitions.

Watch Video Here

SCIEX OS Software

Speed up data processing of calibration lines using automatic outlier removal:
This video looks at speeding up data processing of calibration lines using the automatic outlier removal function.

Watch Video Here

Upgrading to SCIEX OS-MQ Software for processing is easy

Importing processing methods from Analyst® or MultiQuant™ Software to SCIEX OS-MQ Software:
SCIEX OS-MQ Software is the latest innovation from SCIEX in fast, reliable data processing and streamlined review. Combining the powerful features of multiple software platforms into one, it’s a single solution for your data processing needs. But you don’t have to start from scratch! Full MultiQuant Software processing methods can be imported from components to integration parameters to regression settings, so switching to SCIEX OS-MQ Software is simple. Do you have processing methods in Analyst that have long lists of components already set up and don’t want to have to recreate? You can easily import your previously created components from Analyst Software to SCIEX OS Software.

Take your data processing to the next level by taking advantage of the new features such as Automatic Outlier Removal and the Calculated Columns & Flagging Rules. These new features can help reduce processing method development time and data review time, and these helpful videos will show you how to import your methods with ease and confidence.

RUO-MKT-18-10530-A and RUO-MKT-17-10211-A

Why Won’t LipidView™ Software Load My Analyst® Software (.wiff) Data Files?

In order to load Analyst® software data files (.wiff files) into LipidView™ software, either Analyst or Analyst TF software must be installed alongside LipidView. If the data files were acquired with Analyst software, then Analyst software must be installed with LipidView. If the data was acquired with Analyst TF software, then Analyst TF will need to be installed alongside LipidView software. For example, if the data file was acquired on a TripleQuad system with Analyst software, then the data-processing computer with LipidView software will need to have Analyst, not Analyst TF, software installed.

Requirements for installation of LipidView software (see Release Notes):

  • .NET framework 4.0 or higher.
  • Analyst software version 1.6 or higher or Analyst TF software version 1.5 or higher.
  • Microsoft Word 2003 or higher is needed to support reporting functionality.
  • Microsoft Access is not essential. However, it is required for customizing information in the lipid database.

What is the Analyst® Diagnostic Tool and How Can It Help Me?

SCIEX is pleased to introduce the Analyst® Diagnostic Tool! To prevent delays in obtaining the information required to adequately respond to your requests for help with software issues, we have developed the Analyst Diagnostic Tool. With this new tool, we hope to serve you better and more efficiently than ever before.

The Analyst Diagnostic Tool is an information-gathering program that is designed to provide insight on the performance of the computer’s operating system as well as the Analyst software. It does this by streamlining the collection of pertinent information on your PC–including details on the SCIEX computer image, the number and type of installed software programs, the system and application event logs, any recent changes to the computer configuration, the identification of anti-virus applications, and a limited list of configuration settings from the Analyst® Software. The Analyst Diagnostic Tool has been recently piloted in North America, and version 1.0.1 will be released soon.

Installation of the Analyst Diagnostic Tool does not interfere with data acquisition or processing, but it does simplify the gathering of information needed to troubleshoot whether Analyst software or the PC are performing optimally.

The latest version of the Analyst Diagnostic Tool will soon be available to download and install from the SCIEX Software Downloads page located at: https://sciex.com/software-support/software-downloads.

We encourage you to use the Analyst Diagnostic Tool to generate a service package any time you experience an issue with Analyst software. When a service package is generated by the Analyst Diagnostic Tool, a zipped folder containing the compiled information is placed in C:\Service Packages folder. To help us serve you better, this zipped folder can be uploaded directly to your tech support case via the SciexNow portal. Tech support can then access your software information more quickly and start working on a solution to your software issue right away.

For research use only. Not for use in diagnostic procedures.

Echo and Echo MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries and are being used under license.


I'd like to be among the first to get my hands on new SCIEX solutions.

By submitting your information, you agree that SCIEX may collect and further process your personal data in accordance with its Privacy Policy. You may object to receiving further information at any time.